Natixis Global Blood Therapeutics, Inc. Transaction History

Natixis

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$32.4 - $68.18 $5.2 Million - $10.9 Million	-160,400 Reduced 47.6%	176,600 $12 Million
Q2 2022 Aug 12, 2022	SELL	$22.3 - $37.39 $5.96 Million - $9.99 Million	-267,200 Reduced 44.22%	337,000 $10.8 Million
Q1 2022 May 13, 2022	BUY	$25.68 - $35.59 $4.18 Million - $5.79 Million	162,620 Added 36.83%	604,200 $20.9 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $1.49 Million - $2.4 Million	59,645 Added 15.62%	441,580 $12.9 Million
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $2.65 Million - $3.88 Million	103,955 Added 37.4%	381,935 $9.73 Million
Q2 2021 Aug 13, 2021	BUY	$32.46 - $43.42 $9.02 Million - $12.1 Million	277,980 New	277,980 $9.74 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Natixis, based on Form 13F filings with the SEC.

Stay updated on Natixis with notifications on news.